Is FTRE a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Bookings recovery feeding the backlog, with revenue (ttm) at ~$2.68 billion. The bear case rests on revenue is still declining year over year, so the recovery case rests on bookings converting to growth rather than on results already delivered. Analysts covering it are spread from $13.50 to $26.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is still declining year over year, so the recovery case rests on bookings converting to growth rather than on results already delivered. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $13.50, -40.0% from the $22.49 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Bookings recovery feeding the backlog. Fortrea reported a 1.06x book-to-bill in Q2 2026 and ~1.12x over the trailing twelve months, its fourth consecutive quarter above 1.0x. The most optimistic analyst target on FTRE is $26.00, +15.6% from the $22.49 price. That figure is only reachable if this thesis works close to its best case.

Revenue is still declining year over year, so the recovery case rests on bookings converting to growth rather than on results already delivered. Leverage of roughly ~4x adjusted EBITDA leaves less room for error than at peers such as IQVIA or ICON if a downturn in biotech funding or large-pharma budget cuts hits demand, and a weaker year could push the company back toward the covenant and refinancing questions that weighed on the stock in 2025. The finance function has had instability: the newly appointed CFO, Jason Knoblauch, was temporarily barred from serving by a July 2026 court order in a restrictive-covenant dispute with his former employer, leaving board member David Smith as interim CFO. Contract cancellations and delays, a normal feature of the CRO business, can shrink backlog quickly, and Fortrea has a shorter record as an independent company than its peers. The 2025 securities suit was dismissed in September 2026 but could still be appealed. Finally, after a move from ~$8.55 to ~$23 in a year, the share price already reflects a good part of the turnaround that management is describing, so results that only match guidance may not be enough to support it. The most pessimistic published target is $13.50, -40.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Contract research organization spun off from Labcorp that runs clinical trials for drug, biotech and medical device companies.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Bookings recovery feeding the backlog) stalling in the reported numbers rather than in the narrative, the risk above (revenue is still declining year over year, so the recovery case rests on bookings converting to growth rather than on results already delivered) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Fortrea is a contract research organization that runs clinical trials for drug, biotech and medical device companies. Sponsors outsource the work of designing studies, recruiting patients, managing trial sites, collecting and cleaning data and handling regulatory submissions. Fortrea offers that as a full-service package for Phase II to IV trials, runs its own clinical pharmacology units for early Phase I studies, and also provides dedicated staff under functional service provider (FSP) contracts, where its people work inside a client's own systems. It operates in roughly 90 countries and is paid under multi-year contracts, so revenue is recognised as trials progress. That is why its ~$7.8 billion backlog, nearly three years of revenue, matters so much to how investors judge the business, and why bookings today shape results a year or two out.

Fortrea was Labcorp's clinical development business, which itself came largely from Labcorp's 2015 acquisition of Covance. Labcorp spun it off as an independent public company in July 2023, and FTRE began trading on Nasdaq at that point, with Labcorp shareholders receiving Fortrea shares. The separation was harder than planned: Fortrea had to replace finance, IT and other services it had been renting from Labcorp under transition services agreements, which raised costs and hurt margins in 2024 and 2025. Those exit costs, and the revenue expected from pre-spin projects, were central to the 2025 securities lawsuit, which a federal judge dismissed in September 2026. Today the two companies are independent, and Labcorp kept its central laboratory and early development testing businesses.

FTRE has been volatile since the spin-off. The shares fell sharply through 2024 and early 2025 as margins disappointed, including a roughly 25% one-day drop to ~$10.38 on March 3, 2025, and the company took a ~$798 million goodwill impairment in the first half of 2025. Market value sank to roughly ~$850 million by the spring of 2026. As of mid-October 2026 the stock was around ~$22.75, near the top of a 52-week range of roughly ~$8.55 to ~$23.51, after a run of better bookings, cost cuts, an adjusted EPS beat (~$0.23 against ~$0.18 expected) and a guidance raise in July 2026. Past performance does not indicate future returns, and a stock that has moved this much in a year can move sharply in either direction.